Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
MK591
Cat No.
CEI-1431
Description
MK591(Quiflapon sodium) is selective and specific inhibitor of 5-Lipoxygenase-activating protein (FLAP).
Product Overview
IC50: 1.6 nM in a FLAP binding assay for MK-0591, which is the acid form of MK591. Arachidonate 5-lipoxygenase-activating protein is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes. MK-591 (MK-0591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. Clinical trial: In an open-label and pilot study, short-term therapy with MK-591 reduces proteinuria by restoring glomerular size selectivity and thus reduces transglomerular protein trafficking. These benefits may result from glomerular leukotriene biosynthesis inhibition, but other MK-591-specific actions cannot be excluded.
CAS No.
147030-01-1
Molecular Weight
609.15
Purity
0.98
Storage
Store at -20°C
Synonyms
Quiflapon sodium; MK-591; MK 591
Targets
FLAP
Molecular Formula
C34H34ClN2NaO3S
Chemical Name
sodium; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate
Solubility
Soluble in DMSO
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request
In vitro
A series of performed inhibitor studies identified a specific inhibitor of 5-LO (MK-591), which has the ability to block JNK, MAPK and 5-LO signaling-cascades and drastically reducing the activity of pro-inflammatory cytokine TNF-a. Further evaluation of MK-591 utilizing cell proliferation assays in PBMCs, human proximal tubule cells showed a decrease in cell proliferation.
In vivo
Amyloid β peptide (Aβ) deposition in the brains of mice receiving MK-591 was significantly reduced when compared with controls. MK-591 treatment did not cause any change in the steady-state levels ofβ-site amyloid precursor protein cleaving enzyme 1, amyloid-β precursor protein or disintegrin and metalloproteinase domain-containing protein 10.By contrast, MK-591 caused a significant reduction of the γ-secretase complex, at the protein and message level.
Download
Download Datasheet